The latest analyst update on Ginkgo Bioworks Holdings includes a higher fair value estimate of US$8 and at least one price target set at US$11, which points to a reassessment of what investors might be willing to pay for the stock. That shift is closely linked to recent commentary that combines enthusiasm about life science tools and AI-linked demand with a more cautious view on the company's execution and near term fundamentals. Read on to see how these price targets fit into the evolving narrative and how you can track future updates.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
TD Cowen recently raised its Ginkgo Bioworks price target to US$11 from US$9 while keeping a Hold rating. This signals a higher assessed fair value even without a ratings upgrade.
-
The firm highlights what it views as one of the strongest Q3 periods in 20 years for life science tools, with biotech funding and AI related demand supporting a more constructive setup for companies like Ginkgo Bioworks.
🐻 Bearish Takeaways
-
In August 2026, TD Cowen downgraded Ginkgo Bioworks to Hold from Buy and moved its target to US$9 from US$12 after what it described as another sales miss in Q2.
-
The same analyst flagged limited visibility on near term growth and revenue recognition, and suggested investors wait for clearer execution signals before taking a more positive stance.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!
We've flagged 3 risks for Ginkgo Bioworks Holdings. See which could impact your investment.
How This Changes the Fair Value For Ginkgo Bioworks Holdings
-
Fair value moved from US$7 to US$8 based on the latest set of assumptions for Ginkgo Bioworks Holdings.
-
Expected revenue decline widened from 22.87% to 23.01%.
-
Projected profit margin moved from 16.53% to 15.96%.
-
Forward P/E multiple shifted from 75.91x to 88.94x.
-
Discount rate moved from 9.91% to 9.13% in the updated model.
Never Miss an Update: Follow The Narrative
Narratives link Ginkgo Bioworks Holdings' business story to a financial forecast and fair value that refresh as new data and news come through. They help you see how sector trends, company moves, and risks are reflected in analyst expectations over time.
Head over to the Simply Wall St Community and follow the Narrative on Ginkgo Bioworks Holdings to stay up to date on:
-
How the push into life science tools, automated lab systems, and data or AI offerings could affect future revenue mix in a traditionally slow adopting sector.
-
What Ginkgo Bioworks' cost reductions, cash balance of US$474 million, and lack of bank debt may mean for funding its platform shift and automation roadmap.
-
Key risks around sector adoption, underused lab capacity, regulatory and geopolitical scrutiny, and the challenge of monetizing data products in the face of competition and possible commoditization.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include DNA .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
